The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma
Adverse event signals were demonstrated to vary among the three BsAbs used in MM. Significant safety signals identified in the FAERS database which were consistent with previously reported clinical trial data. Furthermore, each BsAb exhibited several novel signals. These findings provide decision-makers and healthcare providers with valuable insights into clinical practice.
Authors
- Erdan Luo (ORCID: https://orcid.org/0000-0001-9342-4547)
- Fan Lai (ORCID: https://orcid.org/0000-0002-0568-2616)
- Yizhen Deng (ORCID: https://orcid.org/0000-0002-3572-1559)
- Bo Wu (ORCID: https://orcid.org/0000-0003-4556-0477)
- Kaili Zhang (ORCID: https://orcid.org/0000-0003-3878-9388)
- Wei Chen (ORCID: https://orcid.org/0000-0002-9394-9834)
- Xia Jiang
- Xiaoling Zhou (ORCID: https://orcid.org/0000-0002-5519-3431)
Institutions
- Kyushu University (JP)
- University of Electronic Science and Technology of China (CN)
- Chengdu Women's and Children's Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-08-13
- DOI
- https://doi.org/10.3389/fmed.2025.1593405
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Department of Science and Technology of Sichuan Province
- Sichuan Provincial Administration of Traditional Chinese Medicine